Heterozygous Familial Hypercholesterolemia (HeFH)
Metabolic·MeSH: Hypercholesterolemia
Prevalence
0.5 / 100K
3 drugs in development·3 companies·2 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 3(1)
| Drug | Company |
|---|---|
| Enlicitide Decanoate | Merck & Co., Inc. (MRK) |
Compare drugs
Frequently asked questions
How many drugs are in development for Heterozygous Familial Hypercholesterolemia (HeFH)?
BioSniper tracks 3 drugs in development for Heterozygous Familial Hypercholesterolemia (HeFH) across 3 companies.
How many clinical trials target Heterozygous Familial Hypercholesterolemia (HeFH)?
There are 2 clinical trials targeting Heterozygous Familial Hypercholesterolemia (HeFH) tracked by BioSniper.
What is the prevalence of Heterozygous Familial Hypercholesterolemia (HeFH)?
The estimated prevalence of Heterozygous Familial Hypercholesterolemia (HeFH) is approximately 0.5 per 100,000 population.
Deep-dive into Heterozygous Familial Hypercholesterolemia (HeFH)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis